Only one-fifth of cancer drugs with accelerated approval have prolonged survival, study finds
The study, published in JAMA Internal Medicine, found that 19 of 93 cancer drugs that won accelerated approval over 25 years improved overall survival, while others only showed improvements on other surrogate endpoints.